Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.

$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.

The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.

Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.